1 BTC
=
- USD
Zymeworks Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Market Statistics
Trading Metrics
How to Buy ZYME
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ZYME
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesZymeworks Inc. announced its participation in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum (May 20), TD Cowen 7th Annual Oncology Innovation Summit (May 27), and 2026 Jefferies Global Healthcare Conference (June 3). The company will engage in fireside chats and one-on-one meetings to discuss its portfolio of licensed healthcare assets and pipeline of novel biotherapeutics.
Zymeworks announced six poster presentations at AACR 2026 showcasing preclinical data from its antibody-drug conjugate (ADC) pipeline, including novel RAS-targeting platforms and multiple first-in-class programs. The company highlighted efficacy and favorable tolerability across solid tumor models, with clinical data from the Phase 1 ZW191 trial to be presented in an oral presentation on April 21.
Zymeworks Inc. announced the full-time appointments of Dr. Adam Schayowitz as Executive Vice President and Head of R&D, and Scott Platshon as Executive Vice President and Chief Business Officer, effective April 9, 2026. Both executives, previously in interim roles, will report to CEO Kenneth Galbraith. The appointments come as Zymeworks focuses on executing its pipeline strategy, managing licensed assets including Ziihera® (zanidatamab-hrii) and pasritamig, and advancing its asset aggregation strategy to drive long-term shareholder value.
Zymeworks Inc. announced the appointment of Kristin Stafford as Chief Financial Officer effective April 1, 2026. Stafford brings extensive experience from Royalty Pharma in strategic planning, capital allocation, and executing complex transactions. The appointment comes as Zymeworks continues advancing its pipeline of biotherapeutics and executing strategic priorities.
Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα) for treating advanced or metastatic platinum-resistant ovarian cancer. The designation expedites development and review timelines for drugs addressing serious conditions with unmet medical needs. ZW191 is currently in Phase 1 clinical trials evaluating safety, tolerability, and anti-tumor activity in patients with advanced solid tumors.